Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OABI vs OABIW: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OABI Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–1 Matrix Metrics)

OABI Overall Winner 6-Pillar Tally: OABI 5 – 0 OABIW (1 Tie) Matrix Metrics: OABI 7 – 1 OABIW

As of Nov 20, 2026, OmniAb, Inc. (OABI) is the stronger overall head-to-head candidate over OABIW (OABIW) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OABI carries a Unified Composite Score of 45.5/100 (HOLD) at $4.66 (N/M Forward P/E, -92.9% operating margin), whereas OABIW carries 49.4/100 (HOLD) at $0.41 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While OABIW currently prints a higher short-term Unified Composite Score (49.4/100 HOLD vs. OABI 45.5/100 HOLD), OABI captures the overall institutional head-to-head verdict (7–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-92.9% vs. N/A operating margin) and revenue trajectory (+78.3% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OABI vs OABIW
OABI NASDAQ Head-to-Head Winner
OmniAb, Inc. Common Stock
Services-Commercial Physical & Biological Research
$4.66
-7.36% 1D
Market Cap $733.7M
TTM Revenue $40M
Forward P/E N/M
Beta / 30D Vol 1.24β · 60% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 15.0 Fund 40.0 Flow 58.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 42.9 · SMA20: $5.03 · SMA50: $4.82
OABIW US Equity
OABIW
Institutional Equity
$0.41
-2.38% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -4.10β · 376% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A

6-Pillar Scorecard Institutional Category Breakdown (OABI 5 – 0 OABIW)

Columns: Metric · OABI · OABIW
1. Valuation Multiples OABI
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 18.1x N/M
2. Growth & Scale OABI
Revenue Growth (YoY) +78.3% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $40M N/A
Market Cap $733.7M N/A
3. Profitability & Quality OABI
Gross Margin 97.7% N/A
Operating Margin -92.9% N/A
Net Profit Margin -108.1% N/A
Return on Equity (ROE) -16.5% N/A
4. Balance Sheet & Cash Flow OABI
Cash Generation (TTM) $2.4M N/A
Cash Flow Margin 5.9% N/A
Net Cash / Leverage $4.7M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OABI
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 101.7% (14th %ile) N/A (N/A)
Put/Call OI Skew 0.04x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OABI (7) vs OABIW (1)
Institutional Metric OABI OABIW Criterion Row Edge
Market Capitalization
Scale
$733.7M N/A Larger Scale OABI
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+78.3% N/A Higher Growth OABI
Operating Margin (TTM)
Profitability
-92.9% N/A Higher Margin OABI
Net Profit Margin
Profitability
-108.1% N/A Higher Margin OABI
Return on Equity (ROE)
Capital Efficiency
-16.5% N/A Higher ROE OABI
52-Week Range Position
Momentum
81% ($1–$5) 63% ($0–$1) Stronger Trend OABI
Beta / 30D Volatility
Risk Regime
1.24β · 60% Vol -4.10β · 376% Vol Lower Realized Risk OABI
Unified Institutional Score
Composite Signal
45.5 / 100 (HOLD) 49.4 / 100 (HOLD) Higher Composite OABIW
Trailing 12M Revenue (USD)
Operating Scale
$40M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
97.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.4M ($4.7M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OABIW +25.27 pp
OABI: +18.84% · OABIW: +44.11%
3M Horizon OABIW +156.73 pp
OABI: +198.83% · OABIW: +355.56%
6M Horizon OABIW +100.3 pp
OABI: +209.7% · OABIW: +310.0%
1Y Horizon OABIW +100.3 pp
OABI: +209.7% · OABIW: +310.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OABI vs OABIW. Trailing 12-month operating profitability (OABI -92.9% vs OABIW N/A) and valuation multiples (OABI N/M vs OABIW N/M Forward P/E) are benchmarked directly in Pillar 4 below.

OABI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40M
Gross Margin97.7%
Op. Margin-92.9%
ROE / Fwd P/E-16.5% · N/M
OABIW ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OABI CONSOLIDATION
17d in phase · OBV NEUTRAL
Current IV 101.7%
IV Percentile 14th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact OABI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OABIW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OABIW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OABI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $733.7M market capitalization and -92.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OABIW Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OABI vs OABIW Key Questions & Quantitative Answers

As of Nov 20, 2026, OmniAb, Inc. (OABI) is the stronger overall head-to-head candidate over OABIW (OABIW) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OABI carries a Unified Composite Score of 45.5/100 (HOLD) at $4.66 (N/M Forward P/E, -92.9% operating margin), whereas OABIW carries 49.4/100 (HOLD) at $0.41 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While OABIW currently prints a higher short-term Unified Composite Score (49.4/100 HOLD vs. OABI 45.5/100 HOLD), OABI captures the overall institutional head-to-head verdict (7–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-92.9% vs. N/A operating margin) and revenue trajectory (+78.3% vs. N/A YoY).

OABI leads the Growth & Scale pillar: OABI posts +78.3% YoY revenue growth and +0.0% YoY earnings growth on $40M TTM revenue (97.7% gross margin, -92.9% operating margin), compared with OABIW at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, OABI generates $40M in USD-normalized revenue versus N/A for OABIW. In operating R&D and SG&A reinvestment, OABI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OABIW.

OABI screens cheaper on headline valuation multiples. OABI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.1x EV/Revenue (5.9% FCF margin), whereas OABIW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OABI (-16.5% ROE) versus OABIW (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, OABI carries 101.7% implied volatility (14th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.24β · 60% Vol realized risk). By comparison, OABIW carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-4.10β · 376% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.